$2.81+0.13 (+4.85%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD
Liminatus Pharma (LIMN) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼187.8%
−10.2
FY21→FY25CAGR —
Free cash flow ($M)▼587.5%
−10.0
FY21→FY25CAGR —
Diluted EPS▼115.0%
−0.43
buyback-liftedCAGR —
What the receipts whisper · what a headline number hides
Share count
−31.1%
34.5mn → 23.8mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level
This filer reports no gross profit or operating income line, so those margins are not drawn.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.4908, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Research & development | 1,000.0 | 0.0 | 2,685.3 | 3,757.0 | 1,853.0 | 3,802.0 | — | — |
Selling, general & admin | 3,065.2 | 2,967.8 | 644.6 | 1,062.0 | 856.0 | 197.0 | ▲360.4% | +97.0% |
Total operating expenses | 4,065.2 | 2,967.8 | 3,330.0 | 2,586.2 | 2,709.0 | 2,534.3 | ▼10.9% | +4.0% |
Operating incomefeeds ROC rank | −4,065.2 | −2,967.8 | −3,330.0 | −2,586.2 | −2,709.0 | −2,534.3 | ▲10.9% | — |
Other income, net | −8,458.1 | −7,238.7 | −216.4 | 1,394.0 | −219.0 | 6,903.9 | — | — |
Pretax income | −12,523.3 | −10,206.5 | −3,546.3 | −1,192.2 | −2,928.0 | 4,369.7 | ▼187.8% | — |
Income tax | — | — | — | 34.0 | 0.0 | 0.0 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −12,523.3 | −10,206.5 | −3,546.3 | −1,226.2 | −2,928.0 | 4,369.7 | ▼187.8% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | — | −0.43 | −0.20 | −0.15 | −0.08 | 0.13 | ▼115.0% | — |
Diluted shares (mn) | — | 23.75 | 17.50 | 8.01 | 34.43 | 34.50 | ▲35.7% | −8.9% |
| Margins | ||||||||
† TTM = trailing four quarters through 2026-06-30.
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-31 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

